Hodgkin's Disease

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

267%

Monoclonal Antibody

133%

+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Ono PharmaceuticalJapan - Osaka

1 program

NivolumabPhase 3Monoclonal Antibody

Prevail TherapeuticsNY - New York

2 programs

R-mabHDPhase 2

PrednisonePhase 1/2

ViiV HealthcareNC - Durham

1 program

I-131 Tositumomab therapeutic regimenPhase 1/2

Sharp TherapeuticsPA - Pittsburgh

1 program

VorinostatPhase 1Small Molecule

MSDIreland - Ballydine

1 program

VorinostatPhase 1Small Molecule

Bristol Myers SquibbPRINCETON, NJ

3 programs

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology PracticesN/A1 trial

MDX-060PHASE_21 trial

R-mabHDPHASE_22 trials

Active Trials

NCT02856646Completed290Est. Sep 2020

NCT00284804Completed74Est. Oct 2009

NCT00816959Unknown1,200Est. Apr 2014

+1 more trials

AstraZenecaCAMBRIDGE, United Kingdom

1 program

TamoxifenN/A1 trial

Active Trials

NCT00165308Completed29Est. Jun 2009

GSKLONDON, United Kingdom

1 program

I-131 Tositumomab therapeutic regimenPHASE_1_21 trial

Active Trials

NCT00484874Completed12Est. Nov 2015

Chugai PharmaJapan - Tokyo

1 program

lenograstimPHASE_2_31 trial

Active Trials

NCT01085058Completed169Est. Dec 2004

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

Bristol Myers SquibbR-mabHD

Chugai Pharmalenograstim

Bristol Myers SquibbR-mabHD

Bristol Myers SquibbMDX-060

GSKI-131 Tositumomab therapeutic regimen

Bristol Myers SquibbHodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

AstraZenecaTamoxifen

Clinical Trials (7)

Total enrollment: 1,894 patients across 7 trials

NCT00816959 Bristol Myers SquibbR-mabHD

Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma

Start: Jul 2011Est. completion: Apr 20141,200 patients

Phase 3Unknown

NCT01085058 Chugai Pharmalenograstim

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Start: May 2003Est. completion: Dec 2004169 patients

Phase 2/3Completed

NCT00797472 Bristol Myers SquibbR-mabHD

Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

Start: Jul 2011Est. completion: Apr 2014120 patients

Phase 2Unknown

NCT00284804 Bristol Myers SquibbMDX-060

A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease

Start: Nov 2005Est. completion: Oct 200974 patients

Phase 2Completed

NCT00484874 GSKI-131 Tositumomab therapeutic regimen

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Start: Jun 2007Est. completion: Nov 201512 patients

Phase 1/2Completed

NCT02856646 Bristol Myers SquibbHodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices

Start: Oct 2016Est. completion: Sep 2020290 patients

N/ACompleted

NCT00165308 AstraZenecaTamoxifen

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Start: Apr 2001Est. completion: Jun 200929 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals

10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.